Omeros Corporation (OMER)

Omeros Corporation is trading at $18.44, down 2.69% on the session. The 50 day average sits at $18.52 and the 200 day at $13.36, which puts the stock in a uptrend. RSI is at 40.2, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $16.50 with resistance near $18.14, so that band frames the current range. Average daily movement is roughly $0.86, or about 4.7% of the share price, which is what any stop placement has to allow for. The overall health score of 43 out of 100 combines a trend score of 64, momentum of 20 and a risk score of 42.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.